Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B63521^11 gp120 + IHV01 gp120
- Development stage
- Unknown
- Lead developer
- GeoVax Labs
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
B63521^11 gp120 and IHV01 gp120 are recombinant HIV-1 envelope glycoproteins (gp120) developed for use as protein boosts in heterologous prime-boost HIV vaccine regimens. B63521^11 is a monovalent CD4-induced (CD4i) gp120 protein, while IHV01 is a transmitted/founder (T/F) gp120 protein. In the HVTN 132 clinical trial, these proteins are administered alongside the MVA/HIV62B vaccine boost following a GEO-D02 DNA prime. The goal of including these proteins is to enhance the induction of protective antibody responses, particularly those targeting the V1V2 region of the HIV envelope, which has been associated with reduced risk of infection in previous trials like RV144. The development is led by the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with the Institute of Human Virology and GeoVax.
- Other names
- gp120 Env proteinsgp-120 Env proteinsgp 120 Env proteinsrecombinant HIV-1 envelope glycoproteinsprotein-National Institute of Allergy and Infectious Diseases (NIAID)-HIV infection
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on B63521^11 gp120 + IHV01 gp120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B63521^11 gp120 + IHV01 gp120.